압타머사이언스, 뉴라메디와 'BBB셔틀 압타머' 신약개발 - 바이오스펙테이터
3/21/2022 12:00:00 AM3 years 1 month ago
by https://www.facebook.com/biospectator/
by https://www.facebook.com/biospectator/
압타머사이언스(Aptamer sciences)는 22일 퇴행성 치료제 개발회사 뉴라메디(Neuramedy)와 뇌혈관장벽(BBB) 셔틀 압타머를 적용한 항체기반 파킨슨병
2020 MOU - (Aptamer sciences) 22 (Neuramedy) (BBB) . 2020 (MOU) . - . . BBB BBB . (tomaralimab) . 2019 . (a-synuclein) TRL2(Toll-like receptor 2) . 15 OPT Congress (Transferrin Receptor, … [+11 chars]
full article...